Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Joel Bloom"'
Publikováno v:
Journal of Clinical Oncology. 40:e13522-e13522
e13522 Background: Adequate reimbursement is considered a prerequisite for adoption of new diagnostic technologies that facilitate patient access to better treatments. Detailed longitudinal investigation of the adoption of new HCPCS codes and the fac
Autor:
Gowhar Shafi, Shivamurthy P.M., Anand Ulle, Krithika Srinivasan, Aravindan Vasudevan, Vikas Jadhav, Dr Sujit Joshi, Nirmal Vivek Raut, Jayant Khandare, Mohan Uttarwar, Kenneth Joel Bloom
Publikováno v:
Journal of Clinical Oncology. 40:3019-3019
3019 Background: Homologous recombination deficient (HRD) tumors are highly responsive to platinum-based chemotherapy and poly (ADP-ribose) polymerase inhibitor (PARPi) therapy. Pathogenic BRCA-1 and BRCA-2 (BRCA1/2) alterations are key members of th
Publikováno v:
2008 Annual Conference & Exposition Proceedings.
Publikováno v:
2007 Annual Conference & Exposition Proceedings.
Publikováno v:
2003 Annual Conference Proceedings.
Autor:
Kenneth Joel Bloom, Dave Smart, Peter Riccelli, Raymond Henderson, Anthony M. Magliocco, Karina Hjort, Bob Holt, Karen Keating, Curtis A. Hanson, Wendy Moore
Publikováno v:
Blood
Introduction Measures taken to mitigate infection spread during the 2020 COVID-19 pandemic are considered to have caused significant unintended consequences on other diseases. Large decreases in the numbers of symptomatic and asymptomatic people pres
Autor:
Isabel Stacey, Jordan Clark, Kenneth Joel Bloom, Nital Patel, Enya Scanlon, Fotios Loupakis, Derry Mae Keeling, Wendy L. Allen
Publikováno v:
Journal of Clinical Oncology. 38:e15667-e15667
e15667 Background: KRAS G12C is a distinctively aggressive, poor survival, tumor genotype conferring resistance to anti-EGFR therapies in lung, colorectal (CRC) and pancreatic cancers. Prospective therapies targeting G12C have demonstrated promising
Publikováno v:
Journal of Clinical Oncology. 38:7528-7528
7528 Background: Acute Myeloid Leukemia (AML) is a devastating disease with poor overall survival. Access to precision medicines, is revolutionizing AML care and is driving an increase in Next Generation Sequencing (NGS) utilization to determine the
Publikováno v:
Journal of Clinical Oncology. 38:e15574-e15574
e15574 Background: The development and launch of first-generation tropomyosin receptor kinase (TRK) inhibitors, such as larotrectinib and entrectinib, has brought targeted treatment options to neurotrophic tropomyosin-related kinase (NTRK) fusion–p
Autor:
Peter Riccelli, Markus Eckstein, Kenneth Joel Bloom, Jordan Clark, Frank Policht, Derry Mae Keeling
Publikováno v:
Journal of Clinical Oncology. 38:e18052-e18052
e18052 Background: Homologous Recombination Repair (HRR) gene mutations result in Homologous Recombination Deficiency (HRD) associated with increased risk of high grade serous ovarian (HGOC) cancer and subsequent response to PARP inhibitors (PARPi).